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"home" patients were those in whom the intention had been to treat at home in more than 60% of courses;
"hospital" patients were those in whom the intention had been to treat in hospital in more than 60% of courses; and "both" patients were those in whom the intention had been to treat in hospital or at home in 40 to 60% of courses.
There were 47 patients (63.8% women) in the "home" group, 51 (41.2% women) in the "hospital" group and 18 (38.9% women) in the "both" group. The mean age of the patients was 26 years (range: 17 to 43) in the "home" group, 26 years (range: 16 to 47 years) in the "hospital" group and 25 years (range: 19 to 42 years) in the "both" group.
Study design
This was a retrospective cohort study that was carried out at the Manchester Adults CF Centre, a specialist centre in Manchester, UK. The patients were mainly allocated to the study groups on the basis of patient preference, which also depended on the severity of the presenting clinical symptoms and the competency of the patient to administer i.v. antibiotics. The length of follow-up was 1 year. Data were missing for 19 of the 454 treatment courses (14 home and 5 hospital patients).
Analysis of effectiveness
All of the patients included in the initial study sample were taken into account in the analysis of effectiveness. However, since some patients received almost equal amounts of home and hospital treatment, the three-group classification system was retrospectively applied. The main outcome measure was the forced expiratory volume in 1 second (FEV1). Treatment days were also reported. For treatment at home, spirometric testing was performed at the start and end of each course of i.v. antibiotics, while in hospital, spirometric testing was performed at admission, twice weekly and at discharge. Two baseline FEV1 values were established in each patient for the 1-year baseline period, which preceded the 1-year study period. The "best" FEV1 was the highest FEV1 during the baseline year, while the "average" FEV1 was the mean of all FEV1 values recorded during that period. The effectiveness of a treatment course was defined as lung function maintained at baseline "best" (i.e. the percentage decline in FEV1 was </=0%). Over the 1-year study period, clinical effectiveness was defined as lung function maintained at baseline "average" (i.e. the percentage decline in FEV1 was </=0%). However, a more realistic definition that took into account the continued decline in lung function in CF patients was a </=2% decline in FEV1. The study groups were comparable at baseline in terms of their demographics and treatment aspects.
Effectiveness results
The 116 patients received 454 courses of intravenous antibiotics during the 1-year study period. "Home" patients had a total mean of 63 days' treatment (range: 10 to 182), with a mean of 52 days at home and 11 days in hospital. "Hospital" patients had a mean total of 54 days' treatment (range: 8 to 308), with a mean of 45 days in hospital and 9 days at home. "Both" patients had a mean total of 66 days' treatment (range: 14 to 166), with a mean of 40 days at home and 26 days in hospital.
In terms of the effectiveness of treatment courses, the mean percentage improvement in FEV1 from their baseline "best" was statistically significantly higher for "hospital" patients than for "home" patients (mean difference 4.6%, 95% confidence interval, CI: 1.8 to 7.4; p=0.001). Overall, 13.6% of courses were classified as "effective". However, statistically significantly more hospital courses were classified as "effective" than home courses (17.4% versus 9.0%; p=0.001).
In terms of the 1-year treatment effectiveness, using the base-case definition (percentage decline in FEV1 </=0%), the effectiveness rate was 42.6% in the "home" group, 58.8% in the "hospital" group and 50% in the "both" group. The mean difference between the "home" and "hospital" groups was 10.1% (95% CI: 2.9 to 17.2; p=0.003).
When the percentage decline in FEV1 was defined as </=2%, the effectiveness rate was 42.6% in the "home" group, 62.7% in the "hospital" group and 55.6% in the "both" group. The difference between the "home" and "hospital" groups was statistically significant, (p=0.045).
